#4 - Gilead Sciences (NASDAQ:GILD)
Gilead Sciences Inc. (GILD) - One of the world’s best known pharmaceutical companies, Gilead Sciences (NASDAQ:GILD) is currently testing the effectiveness of its pneumonia drug, remdesivir, as a treatment for the coronavirus. Gilead is conducting worldwide trials. Although the majority of these trials are in the United States, there are three sites in Singapore and South Korea as well as a randomized, controlled clinical trial in Wuhan, China. The trial will end on April 1 with results coming in May.
In a nod to the speculative nature of what is happening right now, shares of Gilead stock soared nearly 10% when President Trump stated that remdesivir was “essentially approved”. However, the stock has since come off those highs after FDA commissioner Stephen Hahn said testing was not complete, particularly as it related to dosage. Having the right drug, but the wrong dose “can cause more harm than good,” said Hahn at the White House briefing.
Shares of Gilead stock are up over 20% in 2020. GILD is one of the few stocks that have been rising as the broader market is selling off.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More - Current Price
- $90.19
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 14 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $95.41 (5.8% Upside)
